Quinapril: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Quinapril. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Headache | 30% |
| Nausea and/or vomiting | 6% |
| Myalgia | 5% |
| Dizziness | 4.8% |
| Viral infection | 4% |
| Abdominal pain | 4% |
| Upper respiratory infection | 4% |
| Coughing | 3.2% |
| Fatigue | 3% |
| Rhinitis | 3% |
| Back pain | 2% |
| Insomnia | 2% |
| Dyspepsia | 2% |
| Pharyngitis | 2% |
| Vertigo | 2% |
| Chest pain | 2% |
| Diarrhea | 1.4% |
| Somnolence | 1.2% |
| Bronchitis | 1.2% |
| Asthenia | 1.1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.